Podcasts about Urology

What does a urologist actually need to know to confidently manage advanced prostate cancer in the clinic? On this episode of BackTable Urology, host Dr. Ruchika Talwar interviews Dr. Kristen Scarpato, director of the advanced prostate cancer clinic at Vanderbilt University Medical Center, and Dr. Jason Hafron, chief medical officer of the Michigan Institute of Urology. They break down how the landscape has shifted, why more patients stay in urology for treatment, and how to select and monitor therapy based on disease state, comorbidities, and patient goals. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Bayer https://www.bayer.com --- Timestamps 00:00 - Introduction02:41 - Shift to Urology-Led Advanced Prostate Management07:07 - Sorting Therapies by Disease State10:33 - Treatment Intensification and Doublet Therapy17:54 - ARPI Selection and the Four Ps Framework25:46 - Managing Financial Toxicity29:30 - Monitoring, Labs, and Imaging34:11 - Red Flags and Comanagement36:49 - When to Refer to Medical Oncology41:11 - Future Directions and Practice Economics46:33 - Closing Remarks --- More about this episode The discussion covers sorting therapies by disease state rather than drug class, doublet and triplet intensification, the nuances of choosing between abiraterone, enzalutamide, apalutamide, and darolutamide, and Dr. Hafron's “four Ps” framework for drug selection. Dr. Scarpato addresses financial toxicity, surveillance protocols, and red flag symptoms. Both guests share their referral triggers for medical oncology, approaches for oligometastatic disease and metastasis-directed therapy, and practical tips for running an advanced prostate cancer clinic. --- Resources Advanced Prostate Cancer: AUA/SUO Guidelinehttps://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 (JCO)https://ascopubs.org/doi/10.1200/JCO-25-02834 ARACOG (AFT-47): Darolutamide vs Enzalutamide and Cognitive Function, ClinicalTrials.gov NCT04335682https://clinicaltrials.gov/study/NCT04335682 ARASENS: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (NEJM)https://www.nejm.org/doi/full/10.1056/NEJMoa2119115 PSMAddition: 177Lu-PSMA-617 Plus Standard of Care in mHSPC, ClinicalTrials.gov NCT04720157https://clinicaltrials.gov/study/NCT04720157 Medicare Plan Finder, referenced on air for comparing Part D out-of-pocket drug costshttps://www.medicare.gov/plan-compare/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In “Membranous urethral length and post-prostatectomy stress urinary incontinence”, Dr. Béatrice Bouchard (CA) examines membranous urethral length (MUL) as a predictor of continence outcomes after prostatectomy. Based on a retrospective study of 161 men, she shows that patients with post-prostatectomy incontinence have a substantially shorter MUL compared with men presenting urgency incontinence, findings consistent with MRI data. The episode outlines how urethral pressure profiling, performed during routine urodynamics using the Brown and Wickham technique, can reliably measure MUL and provide clinically useful information. Dr. Bouchard highlights the method's potential value for risk stratification, patient counselling, and guiding surgical strategies aimed at preserving urethral length and improving functional outcomes. For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

As routine testosterone screening gains national attention, Nelson Bennett Jr., MD, discusses the importance of symptom-based evaluation, repeat testing, identifying reversible causes of hypogonadism and counseling patients on fertility before treatment. He shares practical guidance for ensuring increased awareness translates into evidence-based, patient-centered healthcare.

Read the full article: https://petronella.ai/blog/wayne-memorial-hospital-regional-urology-settle-data-breach-lawsuits/A conversation about "Wayne Memorial Hospital; Regional Urology Settle Data Breach Lawsuits" from the Petronella Technology Group, Inc. blog.Subscribe to Encrypted Ambition and hear every episode: https://petronellatech.com/podcasts/Questions about AI, cybersecurity, or compliance for your business? Call Petronella Technology Group, Inc. at 919-348-4912.

How can private practice and academic residency programs work together to shape the next generation of urologists? On this episode of BackTable Urology, Dr. Jose Silva interviews Dr. Javier Castillo about launching an academic residency within a busy private urology group in Puerto Rico. They highlight the business, training, and research challenges involved, as well as the innovations that make real collaboration possible. Dr. Castillo also reflects on why building character in trainees is just as important as teaching surgical skill. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction04:04 - Launching a Residency and Building the Practice08:13 - Teaching in the OR and Progressive Responsibility13:58 - Clinic, Administration, and Resident Training16:38 - Expanding BPH Treatment Options25:21 - Creating a Research Culture and AI Projects32:42 - AI Uroflow Project and Follow Up40:21 - BPH Case Workup and Shared Decision-Making47:11 - Patient Goals and Procedure Selection55:43 - Sacral Neuromodulation and New Technologies01:00:19 - Teaching Character and Mentorship01:03:07 - Closing Remarks --- More about this episode The conversation explores how to teach residents in the OR while maintaining efficiency, build a research culture, and leverage advanced technologies like AI-driven home uroflowmetry. Dr. Castillo and Dr. Silva discuss individualized BPH treatment, expanding procedural options, and aligning care with patient goals. The episode closes with practical lessons on mentorship, character, and the strategies that make a residency program thrive for both trainees and patients. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

AI-powered scribes are increasingly available to urologists, but access, adoption, and satisfaction tell different stories. Using findings from the 2025 AUA Census, host Daniel Lee, MD, speaks with Kenneth Nepple, MD, and Giovanni Cacciamani, MD, about the real-world promise and limitations of AI-assisted documentation. They examine workflow integration, time savings, accuracy, clinician oversight, data governance, and privacy—plus what urologists should consider before bringing these tools into practice.

Your testosterone number matters at every age, but most men never learn what theirs should be. Mayo Clinic urologist Dr. Tobias Kohler explains why ~500 is the target, why 1,000 is already running hot, what 2,000+ does to the heart, and why a randomized trial found lifting without steroids beat steroids without lifting. Plus: the blood test that catches heart risk your cholesterol panel misses.Dr. Kohler returns for his second appearance (his first, on erections, testosterone and muscle mass, is one of the most-watched episodes in the show's history). This time: why men's longevity is roughly 50 years behind women's; the Princeton IV consensus he co-chaired, which treats ED as one of the strongest predictors of a future heart attack and points young men toward a coronary calcium scan; the 0–12 ceramide blood test that changes with your behavior; how to get a testosterone baseline that actually means something; what redlining to 2,000–3,000 does to the heart, the set point and the skin; Peyronie's disease, Viagra vs. Cialis, the pills-to-implant ladder, sexual rehab after prostate surgery, and a patient who got stronger with zero testosterone.About Dr. Tobias KohlerTobias S. Kohler, MD, MPH, is Professor of Urology at Mayo Clinic, a fellowship-trained andrologist with 25+ years of clinical and surgical experience and 250+ peer-reviewed publications. He co-chaired the Princeton IV Consensus Guidelines on ED and cardiovascular disease, co-founded the EROS penile implant registry, and co-edited Contemporary Treatment of Erectile Dysfunction (2nd ed.).

For the past 25 years, we've been hearing that male contraceptives are just a few years away. And then a few more… and then some more after that. So for something that has been in development for such a long time, what is with the hold up? In this episode, Dr. Kaylee Byers takes us through the history of birth control – from silk condoms to beaver testicles – before heading back to high school bio for a good old-fashioned male anatomy lesson. Then, urologist Dr. Premal Patel walks us through the current options for males (spoiler alert: not a lot), and endocrinologist Dr. Stephanie Page gives us the lowdown on some of the promising gels, pills, injections and other methods that could finally change the game. So hit play for some sexy science– from vasectomies, to genomics and infertility research, to reproductive equity for all. -Highlights2:18 - The wacky history of contraceptive methods7:54 - Breaking down misconceptions of vasectomies 18:29 - A gel and a frontrunner for male birth control -SourcesThe History and Future of Birth Control - Live ScienceWorld Contraception Day: 10 of history's most horrible contraceptives - BBCBreakthrough takes big step toward safe, reversible male contraception - Cornell

“Good in bed” sounds flattering until you notice what it's really measuring. We've all heard it used like a performance review: skilled, enthusiastic, attentive and focused on someone else's experience. But what do we call a woman who is obviously having a great time, who is fully enjoying her own body? The fact that we don't even have easy words for that says a lot about how women's pleasure has been treated, especially when you're dating after divorce and trying to trust yourself again.In this episode I dig into why wanting more can feel uncomfortable or even “wrong,” and how many of us learned to equate self-denial with being a good woman. I talk a little tiny bit of the science of female anatomy but more about the history of the science of the clitoris as this human body part was largely left unlabeled or omitted in major anatomy resources for decades, shaping what gets taught, studied, and prioritized. We also look at the orgasm gap and the research that points to scripts and habits, not “complicated bodies,” including what actually predicts orgasm for women.Finally, we talk about receiving. If compliments, help, or attention feel like something you have to repay, that pattern shows up in intimacy too. I share a simple permission practice you can start this week plus journal questions to help you reconnect with desire in a grounded, shame-free way. If this hits home, follow the show, share it with a friend who needs it, and leave a review wherever you listen.Citations: Elise Loehnen, On Our Best Behavior: The Seven Deadly Sins and the Price Women Pay to Be Good (2023). https://www.eliseloehnen.com/blog/on-our-best-behaviorOrgasm gap — Frederick, D. A., St John, H. K., Garcia, J. R., & Lloyd, E. A. (2018). "Differences in Orgasm Frequency Among Gay, Lesbian, Bisexual, and Heterosexual Men and Women in a U.S. National Sample." https://pubmed.ncbi.nlm.nih.gov/28213723/O'Connell, H. E., Sanjeevan, K. V., & Hutson, J. M. (2005). "Anatomy of the Clitoris." Journal of Urology. https://pubmed.ncbi.nlm.nih.gov/16145367/ Laurie Mintz, Becoming Cliterate - coined the popular framing of the "orgasm gap" . To download your FREE "Becoming You Again Podcast Map" click here. To schedule your complimentary consult with Karin click here.Struggling after divorce to get to know yourself? Click here to grab my $7 guide to get started!If this podcast resonated with you in any way, please take a minute to follow and give me a rating wherever you listen to podcasts.======================================DISCLAIMER: THE COMMENTARY AND OPINIONS AVAILABLE ON THIS PODCAST ARE FOR EDUCATIONAL, INFORMATIONAL AND ENTERTAINMENT PURPOSES ONLY AND ARE NOT FOR THE PURPOSE OF PROVIDING PSYCHOLOGICAL, COUNSELING OR PROFESSIONAL HEALTHCARE ADVICE. =======================================

How can general urologists recognise when lower urinary tract symptoms may have a neurological cause, and what are the key signs that should prompt further investigation?In this episode, Prof. Sanjay Sinha is joined by Dr. Charalampos Konstantinidis, Dr. Stefania Musco and Prof. Marcio Averbeck to discuss a practical approach to suspecting neurogenic lower urinary tract symptoms in everyday clinical practice.The conversation explores the clinical features that should raise suspicion of an underlying neurological disorder, the importance of a comprehensive history, physical examination and simple diagnostic tests, and how to distinguish neurogenic LUTS from more common urological conditions. The faculty also discuss common clinical scenarios, highlight when further neurological assessment or urodynamic evaluation may be appropriate, and share practical advice to help general urologists avoid missed diagnoses.This podcast is brought to you in collaboration with the EAU Section of Functional Urology.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

What's it really like to transition into urology from another specialty? In this episode, Brandon Sterling sits down with fellow APP Maggie O'Block to discuss their personal journeys into urology and the lessons they learned along the way. Drawing from their own experiences, Brandon and Maggie share practical tips for navigating the learning curve, building confidence in a new specialty, finding mentorship, and adapting to the unique challenges and opportunities of urologic practice. Whether you're considering a move into urology or are just getting started in the field, this candid conversation offers valuable insights, encouragement, and advice to help make your transition a successful one.

Northwell Health recently cut the ribbon on the new Cohen Children's Northwell Health Physician Partners Pediatric Orthopedic Surgery and Urology, opening a new hub for pediatric care for our area. Located at 1111 Marcus Avenue in New Hyde Park, the new location spans 17,000 square feet and features 26 exam rooms. To tell us more, Dr. Jeanine Cook-Garard and Pandora Groth talk with Dr. Jose Prince, the Senior Vice President of Children's Surgery, and the Pediatric Surgeon in Chief, at Northwell Health.

GPs Rebecca and Sarah are joined by consultant urologist at Salford Royal and former Director of Urology for the Greater Manchester Cancer Alliance, Mr Sotonye Tolofari to unpack the complexities of prostate cancer screening, PSA testing, and referral pathways in primary care. This episode covers risk factors—including family history, BRCA variants, Black ethnicity, and age—alongside in-depth discussion on when to offer PSA and DRE, the implications of screening, and the latest updates on targeted programmes. The hosts and guest also address patient counselling, overdiagnosis, and the evolving landscape of evidence and policy around early prostate cancer detection.Recommended cancer key articles:When should primary care be concerned about a family history of prostate cancer?A proactive approach to reducing men's cancer risk and mortality If you loved this episode and would like to hear more like this, please send your review to the-christie.gatewayc@nhs.net and share the series with a colleague.GPs Talk Cancer is the podcast series from GatewayC. GatewayC is the free early cancer diagnosis resource funded by the NHS and is part of The Christie NHS Foundation Trust. View the full shownotes for this episode at Podcast - GatewayCProduced by GatewayC and Listening Dog Media.DISCLAIMER: We know this podcast might be of interest to anybody, however it is aimed at primary care health professionals. All patient cases are based on real stories from our clinical practice as GPs. They are fully anonymised with no identifiable patient data. All featured statistics are accurate at the time of recording. All views expressed by guest speakers are their own. Hosted on Acast. See acast.com/privacy for more information.

Prostate health isn't one-size-fits-all. Let's explore care for everyone, including how gender identity may influence care and how everyone can take charge of their health.

Urologic health affects much more than the prostate. In this episode of Health Matters with the Medicine Center Pharmacy, pharmacist Brad White talks with Dr. Andrew Turk of Aultman Urology about common urologic concerns affecting both men and women. The conversation explores prostate health and prostate cancer, including PSA screening, risk factors, symptoms and advances in prostate cancer management. Dr. Turk also discusses medical and surgical options for men experiencing difficulty urinating. Brad and Dr. Turk also cover women's urologic health, urinary urgency, kidney stone prevention and treatment, vasectomy, blood in the urine, bladder cancer and cystoscopy—along with important signs that may indicate it's time to see a urologist.  Whether you're concerned about prostate health, changes in urination, recurring urinary problems or kidney stones, this episode provides an excellent overview of the conditions urologists diagnose and treat and why you shouldn't ignore persistent urinary symptoms. Read the full article: Urology Health: What Men and Women Should Know Health Matters with the Medicine Center Pharmacy features weekly conversations with local physicians and healthcare professionals designed to help listeners make more informed decisions about their health.

How should short bulbar urethral strictures be assessed and treated and which factors should guide the choice between the available techniques?In this episode, Dr. Marjan Waterloos is joined by Dr. Saskia Morgenstern, Dr. Felix Campos Juanatey and Dr. Leonidas Karapanos to discuss the management of short bulbar urethral strictures and the different treatment options available in clinical practice.The conversation explores the diagnostic work-up of urethral strictures, including the role of urethrography, urethroscopy and patient-reported outcome measures, before discussing the indications for endoscopic treatment and urethroplasty. The faculty compare different surgical approaches, consider how stricture characteristics and patient preferences influence treatment selection, and discuss how outcomes should be evaluated during follow-up. The episode also highlights the importance of looking beyond anatomical success by considering functional outcomes, patient satisfaction and quality of life.This podcast is brought to you in collaboration with the EAU Section of Genitourinary Reconstructive Surgeons.  Their annual meeting takes place in Ghent, (BE) on 24-25 September, where you can expect more on this topic. See details on their website if you would like to join - https://esgurs.uroweb.org/For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, Janelle Marie Traylor, RN, explains common reasons children continue to wet the bed, what's normal in development and when parents should seek medical help. Learn more about Janelle and request an appointment.

The European Urology August 2026 podcast is here! This month we focus on the August 2026 edition of European Urology and are delighted to speak to our Editor-in-Chief, Alberto Briganti, who has picked out three (or four actually!) papers to highlight from the current edition. Plus he  tells us what he has been up to on his Summer holidays!Links to Alberto's Editor's choice papers this month1. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial 2. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer3. Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial4. European Association of Urology Guidelines on Urethral Strictures: Summary of the 2026 Guidelines. Update in Recommendations for Endoluminal Management of Male Anterior Urethral StricturesLink to full contents of August 2026 Even better on our YouTube channelThe European Urology Podcast is produced by the GU Cast team in Melbourne, Australia

Editor at the EAU Central Office and historian Mr. Loek Keizer speaks to urologist Prof. Javier Angulo Cuesta, one of the foremost authorities on Joaquín Albarrán (1860-1912) about Albarrán's storied life and ongoing research into this very interesting period in early urology.After a brief overview of Albarrán's remarkable and legendary career, which took him from Cuba to Paris via Spain, Prof. Cuesta shares some new insights that recently came to light. Recently unearthed poems by Albarrán's hand give a more complete picture of the famous urologist, as an orphaned son, and a man who moved in political and artistic expat circles in Europe.The episode offers a fascinating look at the physician, scientist and man behind one of the most influential names in the history of urology.You can find out more about the life and times of Joaquín Albarrán in the EAU's online European Museum of Urology.The 270-page book Joaquín Albarrán: The Life and Scientific Passion of a Medical Genius by Dr. Marlene Fernández Arias, published by the EAU History Office in 2014 is available for sale in the EAU's online shop.Website of the Spanish Association of Urology's History Office with their Spanish-language publications.This podcast is brought to you in collaboration with the EAU History Office.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

BUFFALO, NY – August 28, 2026 – A new #research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.” The study was led by first author Kelly Crane from the Department of Urology at SUNY Upstate Medical University. The corresponding author is K. R. Seetharam Bhat, who is affiliated with the Department of Urology at SUNY Upstate Medical University and Upstate Urology at MVHS. KRAS is one of the most extensively studied oncogenes in cancer, and the G12C variant has become clinically important following the development of mutation-specific inhibitors. Although KRAS G12C-targeted therapy is established in other malignancies, its frequency and genomic characteristics in genitourinary cancers have remained less well defined. To address this gap, the researchers performed comprehensive genomic profiling of 13,654 tumor specimens from patients with metastatic disease, including 1,453 renal clear cell carcinomas, 3,879 urothelial bladder carcinomas, and 8,322 prostate acinar adenocarcinomas. Tumor mutational burden, microsatellite instability, and PD-L1 expression were also evaluated. Across the full cohort, KRAS alterations were detected in 367 tumors, or 2.7%, while KRAS G12C was identified in only 25 tumors, representing approximately 0.2% of all specimens. No G12C variants were found among the renal clear cell carcinomas. In urothelial bladder carcinoma, 24 of 202 KRAS-altered tumors, or 12%, carried G12C, while only one of 158 KRAS-altered prostate tumors contained the variant. Full press release - https://www.oncotarget.com/news/pr/kras-g12c-mutation-identified-as-a-rare-potential-target-in-genitourinary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28912 Correspondence to - K. R. Seetharam Bhat - bhatkuls@upstate.edu Abstract video - https://www.youtube.com/watch?v=me9HXtnDmp4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28912 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, KRAS mutation, genitourinary malignancy, precision medicine, emerging target To learn more about the journal, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

August 28, 2026In this episode, Scott, Mark, and Dr. Ray Painter review where telehealth stands today and why it is becoming an essential part of the future of urology care. They discuss Medicare's current rules for audio-visual and audio-only visits through 2027, documentation requirements, place-of-service rules, telehealth for hospitalized patients, and the importance of state licensure. The team also looks ahead to Medicare's proposed 2027 group medical visit model and explores how telehealth can improve access, increase efficiency, support remote monitoring, and become a true line of business within a urology practice. The key takeaway: telehealth is no longer just a temporary convenience—it is becoming a foundational part of how practices will deliver care. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

Is an elevated prostate-specific antigen (PSA) the beginning or the end of the prostate cancer workup? On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Tarik Benidir to explore the “PSA problem,” explaining why PSA is biologically useful but clinically imprecise, often leading to false positives, unnecessary biopsies, and detection of indolent disease. They discuss a rational, patient-centered approach to elevated PSA, including when to repeat the test, how to interpret results in the context of age, race, family history, and prostate size, and the use of PSA density and age-adjusted norms instead of rigid cutoffs. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported byCleveland Diagnosticshttps://www.isopsa.com/ --- Timestamps 00:00 - Introduction04:03 - Why PSA Can Be Misleading06:43 - Approach to Elevated PSA and Initial Workup09:51 - MRI, PSA Density, and Biomarker Testing14:31 - Guidelines, Diagnostics, and When to Biopsy20:16 - Comparing 4K, IsoPSA, and Other Biomarkers25:23 - Choosing Between Transperineal and Transrectal Biopsy28:42 - Management Considerations for Elderly and Comorbid Patients33:09 - Active Surveillance, Recurrence, and Long-Term Monitoring40:47 - Key Takeaways and Closing Remarks --- More about this episode The conversation highlights the role of reflex biomarkers, MRI scans, and selective biopsy strategies to reduce unnecessary procedures and focus on identifying clinically significant cancers. Dr. Benidir explains how to weigh MRI results, when to use biomarkers, and how to approach decisions in elderly or comorbid patients. They also discuss new biopsy modalities, active surveillance, and future directions for optimizing PSA-based screening and management. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Veckans recensioner: Axe Africa-burgare, brun tvål, Metalbibeln/Bikerbibeln, Bobbes njursten, långt-bort-akut, Urology for life, hyra powerbank, Super-Bosse, Elitstrykan, svensk film, Dolby surround, att stalka sin brevbärare och att döda en delfin.

We welcome Dr. Lara MacLachlan, Chair of Urology at Albany Medical Center. Aaron Shellow-Lavine hosts.

AUA2026: Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team CME Available: https://cme.auanet.org/URL/FOCUS263ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Analyze emerging data in NMIBC and guideline updates to evaluate the impact of disease recurrence and treatment-related complications on current care pathways and patient outcomes. 2. Apply guideline-driven risk stratification in order to identify and select appropriate patients with high-risk NMIBC for optimal therapy sequencing and escalation of care. 3. Implement strategies for safe and effective integration of novel intravesical and systemic immunotherapies to strengthen multidisciplinary collaboration and shared decision-making between urology and medical oncology. 4. Develop patient-centered, evidence-informed care plans using guideline updates and real-world case examples, in order to address unmet needs, reduce recurrence risk, and improve quality of life for patients with NMIBC. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca ImmunityBio Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC UroGen Pharma, Inc.

In this episode, UROONCO PCa associate editor Dr. Jennifer Le Guévelou speaks with radiation oncologist Prof. Pierre Blanchard on the results of the PEACE 2 phase III randomised trial investigating prophylactic pelvic radiotherapy (RT) targeting pelvic nodal micrometastases and/or cabazitaxel may both reduce the risk of relapse and improve outcomes in patients with very high-risk localised prostate cancer.They discuss the design of the PEACE 2 trial, and its key findings, which showed that whole-pelvic radiotherapy yielded only a minimal trend towards improving clinical progression-free survival, with no significant impact on secondary endpoints, including metastasis-free survival and overall survival. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Urologist Ben Lowentritt (Chesapeake Urology, Baltimore), pops into the studio today while passing through Melbourne. We chat about life in a large urology group practice (a huge part of urology service delivery in the USA), why there appears to be a drop in interest in Fellowship training, and his experience of managing advanced prostate cancer in a large urology group practice. Ben, who is also Secretary of the Large Urology Group Practice Association in the USA, has a lot of interest in gathering real world data from large urology group practices, and shares with us some data on the use of ARPIs in mHSPC which has recently been accepted for publication. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson. 

Send us Fan MailProlapse might be the single most fear-loaded word in postpartum health. Not because of what it is. Because of how little anybody tells you about it.This week we're rewinding to one of our season one conversations, with Dr. Cheryl Iglesia, MD, urogynecologist here in Washington DC and one of the very first mentors I had in pelvic health. My first pelvic health job was at National Rehab Hospital back in 2001, and a couple days a week I was over in her office with absolutely no idea that I was standing next to a LEGEND in the field. (I figured that out later. Much later.)Here's what I want you to hear in this one. She says out loud that part of being a good surgeon is knowing when NOT to operate. Then she spends the rest of the hour showing you what that actually looks like.

In this episode of AUANews Inside Tract, urology PA Chris Pitchford and nurse practitioner Michelle Hellwig share their firsthand experience with the Fundamentals in Urology program. They discuss how the two-day, hands-on course helps APPs build confidence with essential urologic skills, including difficult catheterization, cystoscopy, ultrasound interpretation, and priapism management. The conversation also highlights the value of simulation-based training, peer networking, expert instruction, and early career education for APPs entering or advancing in the specialty. 

Dr. Geo welcomes Dr. Peter Bajic, Medical Director for Urology at Cleveland Clinic Main Campus and Director of Men's Health at the Glickman Urological Institute, for an evidence-based conversation about erectile dysfunction, testosterone, Peyronie's disease, and the biggest myths in men's sexual medicine.They explore why erections reflect cardiovascular health, why "venous leak" is often misunderstood, how GLP-1 medications may temporarily influence testosterone during weight loss, and when testosterone replacement therapy is actually appropriate.The episode also covers Peyronie's disease, treatment options including daily tadalafil and traction therapy, and practical lifestyle changes that can improve both sexual function and long-term health.If you've ever wondered whether ED is psychological, physical, hormonal—or all three—this episode delivers clear answers backed by today's science.In this episode you'll learn:Why erectile dysfunction often predicts cardiovascular diseaseThe truth about "venous leak"How erections actually workPsychological vs. physical causes of EDGLP-1 medications and testosterone explainedWhen testosterone replacement is appropriateThe biggest myths about Peyronie's diseaseDaily Cialis beyond erectile dysfunctionLifestyle strategies that improve sexual healthThe latest treatments available for menTimestamps00:00 Introduction: ED may be your first warning sign02:45 Why erections are a window into overall health06:20 Psychological vs. physical erectile dysfunction13:15 GLP-1 medications, weight loss & testosterone18:30 Combining GLP-1 therapy with testosterone replacement28:45 The truth about "venous leak" explained40:05 Why most men do NOT have true venous leak43:10 The best approach to treating erectile dysfunction49:20 Understanding Peyronie's disease54:20 Can Peyronie's disease be prevented?58:00 Why daily Cialis may be one of men's most useful medications1:01:00 Xiaflex, surgery & future Peyronie's treatments___________________________________

In this episode, UROONCO PCa chief editor Dr. Giancarlo Marra interviews Prof. Mary-Ellen Taplin from Dana–Farber Cancer Institute in the United States, on the results of the PROTEUS trial. The PROTEUS trial is a phase 3, double-blind, placebo-controlled trial evaluating the benefit of adding apalutamide to standard androgen deprivation therapy (ADT) in men with high-risk, localised prostate cancer undergoing radical prostatectomy.They discuss the rationale, patient selection and the results of this trial (dual primary endpoint), as well as the impact of the results on clinical practice. Prof. Taplin concludes in the take-home messages that this trial has illustrated the progress being made in regard to preventing and delaying relapse.To know more on this trial, read the abstract with expert commentary by UROONCO PCa associate editor Assoc. Prof. Pawel Rajwa. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode of AUANews Inside Tract, Dr. Matthew Nielsen and Dr. Peter Clark preview the inaugural AUA Science and Quality Summit, taking place November 13–14, 2026, at AUA headquarters in Linthicum, Maryland. They discuss the vision behind the new meeting, the evolving role of quality improvement in urology, the promise and challenges of artificial intelligence, and the importance of leadership development across career stages.

Welcome to Fertility & Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  Today, we will be discussing the Views and Reviews from the May 2026 edition of Fertility and Sterility entitled "Male Infertility and Immune Function."  This Views and Reviews brought together experts, some of whom we will be interviewing today, who evaluated and summarized the evidence on how the immune system plays a role in male fertility and infertility in general. We know that infertility is caused, at least in part, by a male component in about 50% of cases, and we are appreciative to our guests for joining us in discussion today. We encourage all of our listeners to read the full articles in the journal as we will not be able to cover all the content in this episode. Dr. Michael L. Eisenberg is a Professor of Urology and Obstetrics & Gynecology at the Stanford University School of Medicine.  He is the director of Men's Health at Stanford.  Dr. Eisenberg's NIH-funded laboratory seeks to understand the association between a man's reproductive, sexual, and overall health.  Dr. Marcelo Mass Lindenbaum is a clinical research fellow at the Cleveland Clinic Foundation, soon to be transitioning to his urology residency at Cleveland Clinic Akron General. His primary academic research focuses on male infertility and its relationship with the urologic microbiome, and infection risks associated with prosthetic surgery. Dr. Scott Lundy is a Staff Urologist and Surgeon Scientist at the Cleveland Clinic Foundation who specializes in male reproductive medicine, sexual dysfunction, and microsurgery. Beyond his clinical practice, Dr. Lundy leads significant research efforts, including establishing a multi-institutional consortium to advance the study and treatment of male infertility. View Fertility and Sterility at https://www.fertstert.org/  

In this EAU Podcast episode, "Update in the management of recurrent urinary tract infection", Prof. Chris Harding, Prof. Gernot Bonkat, Assoc. Prof. Kathrin Bausch, Dr. José Medina-Polo and Dr. Carolina Ochoa Vargas discuss the latest evidence and practical approaches for managing recurrent urinary tract infections while supporting antimicrobial stewardship.The episode explores non-antibiotic treatment and prevention strategies, including phytotherapy, immunoprophylaxis, vaginal oestrogen therapy and methenamine hippurate. The speakers review current EAU Guideline recommendations and examine the evidence behind emerging therapies aimed at reducing antibiotic use. Particular attention is given to the management of acute cystitis, prevention of recurrent infections and treatment considerations for patients with neurogenic lower urinary tract dysfunction.The faculty also discuss patient selection, safety considerations and the role of shared decision-making when choosing between available treatment options. Throughout the episode, practical clinical insights are combined with the latest research findings to help clinicians optimise care for patients with recurrent urinary tract infections.This podcast is brought to you in collaboration with the EAU Section of Infections in Urology.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Open vs partial nephrectomy, and open vs robotic prostatectomy - two large randomised trials that did not change surgical practice! Just as important to examine these in GU Cast Journal Club as to examine pivotal trials that did change practice. Today we discuss the EORTC Today we discuss the EORTC 30904 RCT looking at kidney cancer surgery (Eur Urol 2011), and the Brisbane randomised trial of open vs robotic prostatectomy conducted (Lancet 2016). We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. AN emotional one as Carlos is heading home to Mexico soon! Links to papers below:1. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma Eur Urol 2011 2. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study Lancet 2016Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

July 17, 2026In this episode, Scott and Mark Painter provide their initial analysis of CMS's proposed 2027 Medicare Physician Fee Schedule and highlight the changes most likely to impact urology practices. The discussion covers the proposed conversion factor reduction, a significant new proposal to apply the multiple procedure payment reduction to E/M services billed with modifier 25, changes to G2211, updates to practice expense methodology, prostate biopsy coding revisions, telehealth proposals, and a substantial reimbursement increase for bulking agent injections. The team also shares practical insight into what these proposals could mean for physician compensation, practice operations, and future commercial payer policies. The key takeaway: while the rule is still only proposed, now is the time for urology practices to understand the changes, submit meaningful comments, and begin planning for what could be a very different reimbursement landscape in 2027. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

How should prostate biopsy be performed in the MRI era, and what impact does biopsy strategy have on treatment planning?In this episode, Prof. Francesco Sanguedolce is joined by Prof. Francesco Giganti, Prof. Gianluca Giannarini and Prof. Lars Budäus to discuss the latest expert recommendations on prostate biopsy.The conversation explores the importance of high-quality MRI, targeted and perilesional biopsy strategies, the role of emerging imaging technologies and the ongoing debate surrounding systematic biopsy.The faculty also discuss how biopsy findings can influence decisions on focal therapy, nerve-sparing surgery and lymph node dissection, while highlighting current areas of consensus and the questions that still remain in clinical practice.ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy, European Urology, article in press. Doi.org/10.1016/j.eururo.2026.06.012)This podcast is brought to you in collaboration with the EAU Section of Urological Imaging.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary teams must prioritize collaborative workflows at all points of the treatment journey. In this episode, CANCER BUZZ speaks with Manojkumar Bupathi, MD, President of Rocky Mountain Cancer Centers, about how ADCs are reshaping the care model toward earlier, structured collaboration between urology and medical oncology. Guests: Manojkumar Bupathi, MD President Rocky Mountain Cancer Centers Co-Chair, GU Executive Committee Sarah Cannon Research Institute Denver, CO "The challenge wasn't learning the drug itself. The challenge was how you integrate the regimen into your treatment paradigm." —Manojkumar Bupathi, MD "There's always this relationship that happens from the beginning and is maintained throughout the entire process." —Manojkumar Bupathi, MD Resources: ACCC Bladder Cancer Resources ACCC Antibody-Drug Conjugate Resources  

Is print medical literature officially dead, or are we just drowning in a digital sea of unread journal articles? On this episode of the BackTable Industry Podcast, host Anish Parikh sits down with Dr. George Koch, an attending reconstructive urologist at The Ohio State University and early career editor for the Journal of Urology, to discuss the realities of staying clinically current in a rapidly evolving field. They explore how digital platforms, subspecialty meetings, and peer mentorship are shaping the future of education, collaboration, and device adoption in reconstructive urology. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 02:55 - Embracing Multiple Learning Platforms 04:13 - Staying on Top of New Literature 08:26 - Behind the Scenes: Editorial Insights11:44 - Rise and Fall of “UroTwitter”15:50 - GURS Meeting Value21:49 - Pathways to Device Adoption25:53 - Decoding Industry Signal and Noise29:16 - Closing Remarks --- More about this episode Dr. Koch emphasizes that while podcasts serve as an excellent supplement, staying clinically current requires a multi-medium approach. He highlights the immense clinical value of Genitourinary Reconstructive Surgeons (GURS) meetings for practical surgical techniques and video reviews, contrasting them with the broader American Urological Association (AUA) sessions that tend to spark academic research questions. He reflects on the shift from print to digital journal alerts, the decline of the once-vibrant "UroTwitter" community, and how peer trust, rather than marketing noise, dictates the clinical adoption of new medical devices and biologics. --- Resources Kerecis Fish Skin Graft Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11015860/ Optilume Clinical Trialshttps://www.laborie.com/news/laborie-announces-first-procedures-in-endure-1-study-with-the-optilume-ureteric-drug-coated-balloon/ --- Backtable Industry is the go-to podcast for healthcare leaders, business-minded providers, and innovators that are shaping the future of healthcare. Download the free BackTable app to get early access to new episodes. ► https://www.backtable.com/app

What opportunities and challenges does private equity bring to urology practices, and how can physicians engage in ways that strengthen their practice and preserve clinical priorities? On this episode of BackTable Urology, Dr. Ruchika Talwar interviews Dr. Benjamin Lowentritt of Chesapeake Urology and United Urology Group to unpack the realities of private equity involvement in medicine. They discuss the motivations behind consolidation, the role of management services organizations, and strategies for building mutually beneficial partnerships while upholding physician autonomy and patient care. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:58 - Why Urology Drew Private Equity07:06 - Bad Headlines vs. Reality11:14 - MSOs and Contracts Explained15:24 - Timelines and After Private Equity22:47 - Efficiency and Autonomy Fears27:15 - Why Private Equity Gets Vilified31:23 - Young Urologist Job Market35:42 - Advice for New Grads40:26 - Urology in 2035 and Fair Critiques of Private Equity44:40 - Closing Thoughts --- More about this episode Dr. Lowentritt outlines the history of private equity in healthcare, noting that consolidation predated private equity and was driven by payer and hospital market power, reimbursement pressure, administrative burden, staffing, and capital needs. He distinguishes private equity's role in hospitals from physician practice management, describing management services organization (MSOs) as structures that handle back-office functions and provide capital while preserving physician control over patient care and local governance. He also discusses private equity's limited investment timeline, shaped by the ultimate goal of selling a profitable company, and potential end-states such as acquisition or public ownership, reflecting on his own experiences with United Urology's acquisition. The conversation further explores recruiting new graduates, evolving partner tracks, mentorship, and maintaining physician leadership to preserve independent practice. --- Resources Dr. Benjamin Lowentritt is the current treasurer of LUGPA (Large Urology Group Practice Association) https://www.lugpa.org/, the Chesapeake Urology group (https://chesuro.com/), and United Urology Group (which was acquired by One Oncology https://www.oneoncology.com/UnitedUrologyGroup/). One Oncology eventually was acquired by Cencora (https://www.cencora.com/). Dr. Benjamin Lowentritt email: blowentritt@chesuro.com --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

As new data reshape treatment discussions for high-risk localized prostate cancer, understanding the nuances behind the evidence is critical. Ashley E. Ross, MD, PhD, a member of the PROTEUS (Perioperative Treatment with Erleada United with Surgery) steering committee, offers an insider's perspective on the landmark trial, including how it's adding options for standard of care.

Artificial intelligence is transforming prostate cancer care faster than ever before but could it one day replace the traditional biopsy?In this episode, Dr. Geo sits down with Dr. Wayne Brisbane, Assistant Professor of Urology and urologic oncologist whose research is helping redefine how prostate cancer is detected and treated. After earning his medical degree from Loma Linda University School of Medicine, completing his urology residency at the University of Washington, and a fellowship in Urologic Oncology at UCLA, Dr. Brisbane has become one of the leading voices in AI-driven prostate cancer diagnosis.His clinical practice and research focus on image-guided biopsy, MRI, PSMA PET imaging, micro-ultrasound, and focal therapy—helping patients receive more precise treatment while minimizing unnecessary side effects. UCLA remains one of the few centers in the world advancing all of these technologies under one program.Together, Dr. Geo and Dr. Brisbane explore how artificial intelligence is improving MRI interpretation, helping physicians better map prostate tumors, identify the best candidates for focal therapy, and potentially reduce the need for invasive biopsies in the future.If you're navigating a prostate cancer diagnosis or simply want to understand where prostate cancer care is headed this conversation offers a fascinating look at the next generation of precision medicine.Episode Chapters00:00 Introduction03:00 AI Is Changing Prostate Cancer Diagnosis07:00 Unfold AI: Mapping Tumors with Greater Precision10:00 Who Is the Right Candidate for Focal Therapy?13:00 Life After Focal Therapy: MRI, PSMA & Monitoring15:00 Focal Therapy vs. Surgery: What the Latest Research Shows21:00 Can AI Eventually Replace the Prostate Biopsy?25:00 Dr. Brisbane's Vision for the Future of Diagnosis29:00 Cribriform Disease: Identifying High-Risk Cancer32:00 Beyond DNA: How Proteomics May Transform Cancer CareKey Takeaways✅ How AI is making prostate cancer diagnosis more accurate✅ Why MRI can still miss clinically significant prostate cancer✅ The technology behind Unfold AI and personalized tumor mapping✅ Who is—and isn't—a good candidate for focal therapy✅ Why tumor size plays a critical role in treatment decisions✅ Can AI eventually replace the prostate biopsy?✅ The latest research comparing focal therapy and surgery✅ Why prospective clinical trials matter when evaluating new treatments✅ How MRI, PSMA PET, genomics, and AI are shaping the future of prostate cancer care✅ Dr. Wayne Brisbane's vision for the next generation of precision prostate cancer diagnosisResources MentionedUnfold AI (Avenda Health)MRI for prostate cancerPSMA PET imagingFocal TherapyActive SurveillanceUCLA Prostate Cancer ResearchStanford validation studiesCAPTAIN TrialFARP TrialHIFU clinical studies___________________________________

Ep. #812 | One of the most critical habits for improving erections, and a simple mental approach to help you get it done.Inquiries: contact@holisticalpha.comStudiesKhera M, Bhattacharyya S, Miller LE. (2023). Effect of aerobic exercise on erectile function: Systematic review and meta-analysis of randomized controlled trials. Journal of Sexual Medicine.https://academic.oup.com/jsm/article/20/12/1369/7301709https://pubmed.ncbi.nlm.nih.gov/37814532/Gerbild H, Larsen CM, Graugaard C, Areskoug Josefsson K. (2018). Physical activity to improve erectile function: A systematic review of intervention studies. Sexual Medicine.https://pmc.ncbi.nlm.nih.gov/articles/PMC5960035/Silva AB, Sousa N, Azevedo LF, et al. (2017). Physical activity and exercise for erectile dysfunction: Systematic review and meta-analysis. British Journal of Sports Medicine.https://pubmed.ncbi.nlm.nih.gov/27707739/Esposito K, Giugliano F, Di Palo C, et al. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA.https://jamanetwork.com/journals/jama/fullarticle/198993Begot I, Peixoto TC, Gonzaga LR, et al. (2015). A home-based walking program improves erectile dysfunction in men with an acute myocardial infarction. American Journal of Cardiology.https://pubmed.ncbi.nlm.nih.gov/25727080/Maio G, Saraeb S, Marchiori A. (2010). Physical activity combined with PDE5 inhibitor therapy improves erectile function more than medication alone.https://pubmed.ncbi.nlm.nih.gov/20367777/Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. (2006). A prospective study of risk factors for erectile dysfunction. Journal of Urology.https://pubmed.ncbi.nlm.nih.gov/16753404/Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. (2000). Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Journal of Urology.https://pubmed.ncbi.nlm.nih.gov/10731462/Dorey G, Speakman M, Feneley R, Swinkels A, Dunn C. (2004). Randomized controlled trial of pelvic floor muscle exercises and biofeedback for erectile dysfunction. BJU International.https://pubmed.ncbi.nlm.nih.gov/15527607/Chen Z, et al. (2024). Effect of different physical activities on erectile dysfunction: A systematic review and network meta-analysis. Andrology.https://onlinelibrary.wiley.com/doi/full/10.1111/andr.13682

Matthew Davenport MD MBA is Professor of Radiology and Urology, Service Chief, and Executive Vice Chair in the Department of Radiology at Michigan Medicine. He also is Co-Director of the Weiser Center for Prostate Cancer. Dr. Davenport is a co-author on national policy statements and has published over 250 peer-reviewed manuscripts. He is frequently interviewed […] The post Communicating About Incidental Findings and Other Uncertain Conditions (HLOL #273) appeared first on Health Literacy Out Loud Podcast.

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net.Today on the emDOCs cast with Brit Long (@long_brit), we cover the potentially deadly infected ureterolithiasis. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle PlaySend us Fan Mail

June 26, 2026In this episode, Scott, Mark, and Dr. Ray Painter continue their discussion on buy-and-bill drugs, using ZUSDURI® as a case study to explore the clinical, operational, and reimbursement challenges facing urology practices. The conversation covers prior authorizations, payer eligibility checks, documentation requirements, medical record reviews, RAC audits, and strategies for successfully introducing new drug therapies into a practice. The team also discusses the importance of standardized protocols, staff training, monitoring reimbursement, and leveraging technology to reduce financial risk. The key takeaway: successful buy-and-bill programs depend on more than getting paid—they require the right processes to ensure practices get paid, keep the payment, and continue delivering innovative therapies to patients. PRS Coding and Reimbursement HubAccess the HubBotox LCD AlertDownload the AlertFree In-Office Prostate Biopsy Calculator (Suppoted by UC-Care)Download NowPRS Coding CoursesFor UrologistFor APPsFor Coders, Billers, and Admins Join the Urology Pharma and Tech Pioneer GroupEmpowering urology practices to adopt new technology faster by providing clear reimbursement strategies—ensuring the practice gets paid and patients benefit sooner.         https://www.prsnetwork.com/joinuptpClick Here to Start Your Free Trial of AUACodingToday.com   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ 

What if one of the most important health crises affecting men today wasn't being caused by aging, but by the environment we live in? In this eye-opening solo episode, Darin Olien investigates the alarming decline in testosterone levels, fertility, and reproductive health among men worldwide. Drawing on decades of research, epidemiological studies, environmental science, endocrinology, and public health data, Darin examines the growing evidence connecting endocrine-disrupting chemicals, microplastics, sleep deprivation, chronic stress, poor lifestyle habits, and environmental toxins to declining testosterone levels across generations. From BPA, phthalates, atrazine, PFAS, and microplastics to sleep quality, circadian rhythms, cholesterol metabolism, cortisol regulation, and natural testosterone-supporting strategies, this episode explores what may be one of the most underreported public health issues of our time—and what men can do to take control of their health today.     What You'll Learn Why testosterone levels have been declining for decades The startling research on global sperm count decline How endocrine-disrupting chemicals interfere with hormone production Why BPA and phthalates may disrupt testosterone synthesis The role of atrazine, PFAS, and environmental toxins How chronic stress diverts resources away from testosterone production Why sleep may be the most important testosterone intervention The connection between cholesterol and hormone production How microplastics are being found throughout the human body The surprising relationship between statins and testosterone levels Natural lifestyle strategies that support healthy hormone production Practical steps to reduce environmental exposure and improve health     Chapters 00:00:00 – Welcome to SuperLife 00:00:33 – Sponsor: Fatty15 and cellular health 00:04:17 – The testosterone collapse explained 00:04:51 – Testosterone levels have been declining for decades 00:06:03 – Global sperm count decline and accelerating trends 00:07:02 – Why treating symptoms misses the root cause 00:07:27 – The hidden public health crisis 00:08:03 – Why low testosterone isn't just about aging 00:09:12 – Why hormone health affects longevity 00:09:53 – Low testosterone and increased mortality risk 00:10:35 – Testosterone's role in metabolism and cardiovascular health 00:11:27 – Endocrine-disrupting chemicals and hormone disruption 00:12:44 – BPA and its effects on testosterone production 00:13:59 – Phthalates and their impact on hormone pathways 00:16:00 – Glyphosate, atrazine, and pesticide exposure 00:17:07 – PFAS and reproductive health concerns 00:17:55 – Environmental toxins and population-wide effects 00:18:11 – Sponsor: Shakeology 00:20:02 – Cholesterol and hormone production 00:20:53 – Chronic stress and cortisol dominance 00:21:45 – Actionable solutions begin 00:21:56 – Why sleep is essential for testosterone production 00:23:07 – How sleep deprivation rapidly lowers testosterone 00:23:21 – Light pollution and circadian disruption 00:23:41 – Foods and nutrients needed for hormone health 00:24:23 – Microplastics and testicular tissue 00:24:53 – Statins and unintended hormonal consequences 00:25:39 – A practical testosterone sovereignty protocol 00:25:48 – Water filtration and reducing toxic exposure 00:26:13 – Eliminating plastics and fragrance chemicals 00:26:35 – Why organic food matters 00:26:45 – Sunlight and vitamin D 00:27:05 – Magnesium, omega-3s, and iodine 00:27:26 – Pine pollen and natural androgen support 00:28:01 – Tongkat Ali and ashwagandha 00:28:48 – Strength training and lifestyle interventions 00:29:10 – Habits that naturally support testosterone 00:29:27 – Darin's approach to healthy aging 00:29:37 – Plants, herbs, and common sense 00:29:51 – Reclaiming your health and sovereignty 00:30:00 – Final thoughts and closing message     Thank You to Our Sponsors Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. Shakeology: Get 15% off with code DARINO1BODI at Shakeology.com.     Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien     Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness     Key Takeaway "The testosterone crisis may be about far more than aging. It may be a reflection of the modern environment itself—one increasingly saturated with endocrine-disrupting chemicals, chronic stress, poor sleep, circadian disruption, and toxic exposures. While many of these forces feel outside our control, the encouraging reality is that many of the most powerful interventions remain accessible: improving sleep, reducing toxic load, eating whole foods, getting sunlight, managing stress, exercising regularly, and reclaiming responsibility for our health. The goal isn't fear. The goal is awareness—and action."     Bibliography/Sources: The Decline — Primary Research Levine, H., Jørgensen, N., Martino-Andrade, A., et al. (2022). Temporal trends in sperm count: A systematic review and meta-regression analysis of samples collected globally in the 20th and 21st centuries. Human Reproduction Update, 29(2), 157–176. https://doi.org/10.1093/humupd/dmac035 Lokeshwar, S. D., Patel, P., Fantus, R. J., et al. (2021). Decline in testosterone levels in men aged 15–40: Results from the National Health and Nutrition Examination Survey (NHANES), 1999–2016. World Journal of Urology, 39(2), 447–452. https://doi.org/10.1007/s00345-020-03227-1 Spital Clinic. (2026, March). Declining testosterone levels by generation. https://www.spitalclinic.com Travison, T. G., Araujo, A. B., O'Donnell, A. B., Kupelian, V., & McKinlay, J. B. (2007). A population-level decline in serum testosterone levels in American men. The Journal of Clinical Endocrinology & Metabolism, 92(1), 196–202. https://doi.org/10.1210/jc.2006-1375 Low Testosterone — Mortality & Disease Risk Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013). Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169(6), 725–733. https://doi.org/10.1530/EJE-13-0321 Shores, M. M., et al. (2006). Low testosterone associated with increased all-cause and cardiovascular mortality. Archives of Internal Medicine, 166(15), 1660–1665. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/410754 Yeap, B. B., Marriott, R. J., Dwivedi, G., et al. (2024). Associations of testosterone and related hormones with all-cause and cardiovascular mortality and incident cardiovascular disease in men. Annals of Internal Medicine. https://doi.org/10.7326/M23-2781 Endocrine Disrupting Chemicals Associations between endocrine-disrupting chemical exposure and fertility outcomes: A decade of human epidemiological evidence. (2024). PubMed Central (PMC12299029). https://pmc.ncbi.nlm.nih.gov/articles/PMC12299029/ Hayes, T. B., Haston, K., Tsui, M., et al. (2002). Herbicides: Feminization of male frogs in the wild. Nature, 419, 895–896. https://doi.org/10.1038/419895a Mechanisms of testicular disruption from exposure to BPA and phthalates. (2020). Journal of Clinical Medicine, 9(2), 471. https://pmc.ncbi.nlm.nih.gov/articles/PMC7074154/ Meeker, J. D., Calafat, A. M., & Hauser, R. (2014). Urinary phthalate metabolites and their biotransformation products: Predictors and temporal variability among men and women. Journal of Exposure Science & Environmental Epidemiology. https://www.sciencedaily.com/releases/2014/08/140814124330.htm Zhao, Q., et al. (2023). Male reproductive toxicity of microplastics: Head and tail of the sperm. Science of the Total Environment, 872, 162181. https://doi.org/10.1016/j.scitotenv.2023.162181 Zhong, B., et al. (2024). Mixed EDC exposure associated with reductions in testosterone and free androgen index. Scientific Reports. https://doi.org/10.1038/s41598-024-76972-z Cortisol, Stress & the HPG Axis Bielohuby, M., et al. (2012). Swiss military cadets prolonged stress study. Psychoneuroendocrinology. Preprints.org. (2025). Sleep deprivation: A modifiable cause. https://doi.org/10.20944/preprints202505.0580.v1 SiPhox Health. (n.d.). Summary of Journal of Clinical Endocrinology & Metabolism data. https://www.siphoxhealth.com Viau, V. (2002). Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. Journal of Neuroendocrinology, 14(6), 506–513. https://doi.org/10.1046/j.1365-2826.2002.00798.x Sleep & Testosterone Leproult, R., & Van Cauter, E. (2011). Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA, 305(21), 2173–2174. https://jamanetwork.com/journals/jama/fullarticle/1029127 Reiter, R. J., et al. (2021). Melatonin and male reproductive health: Relationship to oxidative stress, mitochondrial function, and Leydig cell protection. Endocrine. Tan, D. X., Hardeland, R., Manchester, L. C., et al. (2023). Melatonin as a pleiotropic antioxidant hormone. Journal of Pineal Research. Nutrition — Zinc, Vitamin D, Cholesterol Corona, G., et al. (2010). Statin therapy and testosterone levels in men: A systematic review. The Journal of Sexual Medicine. Daniell, H. W. (2002). Hypogonadism in men consuming sustained-action oral opioids. The Journal of Pain, 3(5), 377–384. https://doi.org/10.1054/jpai.2002.126790 Pilz, S., Frisch, S., Koertke, H., et al. (2011). Effect of vitamin D supplementation on testosterone levels in men. Hormone and Metabolic Research, 43(3), 223–225. https://doi.org/10.1055/s-0030-1269854 Prasad, A. S., Mantzoros, C. S., Beck, F. W., Hess, J. W., & Brewer, G. J. (1996). Zinc status and serum testosterone levels of healthy adults. Nutrition, 12(5), 344–348. https://doi.org/10.1016/S0899-9007(96)80058-X Natural Testosterone Support — Botanical Evidence Pine pollen impacts testosterone-related symptoms in men. (2024). ACMCR Case Reports, 14(5), 1–9. Chinnappan, S. M., George, A., et al. (2021). Effect of Eurycoma longifolia standardised extract Physta on testosterone levels in ageing males: A randomised, double-blind, placebo-controlled multicentre study. Food & Nutrition Research, 65. https://doi.org/10.29219/fnr.v65.5647 Lazarev, A., & Bezuglov, E. (2021). Testosterone boosters intake in athletes: Current evidence and further directions. Endocrines, 2(2), 109–120. https://doi.org/10.3390/endocrines2020011 Leisegang, K., et al. (2022). Eurycoma longifolia (Tongkat Ali) improves serum total testosterone in men. Food & Nutrition Research. https://pubmed.ncbi.nlm.nih.gov/36013514/ Leitão, A. E., et al. (2021). 6-month double-blind RCT: Eurycoma longifolia 200mg + concurrent training. Maturitas. https://doi.org/10.1016/j.maturitas.2020.10.005 Lopresti, A. L., Smith, S. J., et al. (2019). An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract. Medicine, 98(37), e17186. https://doi.org/10.1097/MD.0000000000017186 Pandit, S., Biswas, S., Jana, U., De, R. K., Mukhopadhyay, S. C., & Biswas, T. K. (2016). Clinical evaluation of purified shilajit on testosterone levels in healthy volunteers. Andrologia, 48(5), 570–575. https://doi.org/10.1111/and.12482 Saden-Krehula, M., Tajic, M., & Kolbah, D. (1971). Testosterone, epitestosterone and androstenedione in the pollen of Scotch pine Pinus sylvestris L. Experientia, 27(1), 108–109. https://doi.org/10.1007/BF02137731 Wankhede, S., Langade, D., Joshi, K., et al. (2015). Examining the effect of Withania somnifera supplementation on muscle strength and recovery: A randomized controlled trial. Journal of the International Society of Sports Nutrition, 12, 43. https://doi.org/10.1186/s12970-015-0104-9

Dr. Gabriela Gonzalez and medical student Margaret Dearey share their experiences with the AUA's FUTURE Program at AUA2026, highlighting how mentorship, early exposure, and community support can shape career paths. From navigating a first AUA Annual Meeting to building meaningful connections, they discuss the program's impact from both mentor and mentee perspectives, and why others should get involved.

Most men think erectile dysfunction is a bedroom problem and low testosterone is just a fact of getting older. This roundtable makes the case that both are early warning lights for your heart, your metabolism, and your long-term health and that ignoring them can cost you a decade.In this episode, Dr. Gabrielle Lyon sits down with urologists and men's health specialists Dr. Mohit Khera, Dr. Larry Lipshultz, and Dr. Tobias Köhler to discuss:Why a 35-year-old with ED carries a ~15% risk of heart attack or stroke within 7 years, ~3.5x the risk of depression, and ~30% odds of diabetes or prediabetes and why a prescription alone misses all of itWhy "age-related" testosterone decline is largely a misnomer: a healthy man shouldn't drop significantly with age, so falling T usually signals something reversible underneathHow testosterone became the single best blood marker of a man's overall health, and the case for annual screening that almost no man getsWhat the TRAVERSE trial changed when the FDA removed testosterone's cardiovascular warning in 2025, debunking the prostate-cancer and heart-attack fearsThe 2-minute monthly self-exam every man should do to catch testicular cancer early, when it's ~99% curableIf you've been told your symptoms are "just aging" or you love a man who refuses to see a doctor. This conversation shows you how to read the signals your body gives long before a crisis hits.Thank you to our sponsors:Body Health - Use the code LYON20 to get 20% off your first order https://bit.ly/4efgBuMTimeline - Get 20% off your Mitopure order at https://bit.ly/49LSbYzBranch Basics - Save 15% at https://bit.ly/4uuw4x3 with code DRLYONExplore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Larry Lipshultz at:Instagram: https://www.instagram.com/lipshultzmd?igsh=NTc4MTIwNjQ2YQ==Website: https://www.larrylipshultz.com/YouTube: https://www.youtube.com/@DrsAmyandLarryFind Dr. Tobias KohlerInstagram: https://www.instagram.com/tobiaskohlermd?igsh=NTc4MTIwNjQ2YQ==X: https://x.com/sexhealthmd?s=11Find Dr. Mohit KheraInstagram: https://www.instagram.com/drmohitkhera?igsh=NTc4MTIwNjQ2YQ%3D%3DX: https://x.com/DrMohitKheraWebsite: https://drmohitkhera.com/Connect with Dr. Gabrielle Lyon:Instagram: https://www.instagram.com/drgabriellelyon/TikTok: @drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction01:30 - What doctors got wrong about testosterone05:05 - The prostate cancer myth, debunked07:12 - The best marker of a man's health11:51 - Is age-related decline actually real?14:15 - How obesity crushes testosterone18:11 - Testosterone and reversing diabetes20:06 - GLP-1 versus testosterone25:20 - What "low testosterone" really means29:05 - Dosing, CAG repeats, and microdosing42:34 - The TRAVERSE trial and FDA reversal47:10 - The prostate saturation point56:49 - Peptides, explained01:03:00 - Why ED is a check engine light01:08:26 - The desert of men's health care01:11:06 - The case for annual screening01:16:45 - Varicoceles and male fertility01:20:03 - How to check for testicular cancer01:26:44 - Final advice for menIf you found this episode valuable, share it with someone who would benefit from it.Disclaimers: This episode includes paid sponsorships.The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.

Although we speak a lot about women's health on The Midpoint, it's also important to look at men's health and what we should take notice of. Kenny's diagnosis changed a lot of things with regards to our awareness of health and proved that we should always get ahead of what can go wrong or actually look for the signs before something really does become an issue.Today's guest is someone who is at the absolute forefront of Men's Health in this country. Professor Vaibhav Modgil is a Consultant Urological Surgeon at Manchester Royal Infirmary and one of the UK's leading experts in andrology — which is essentially the study of male health and the male reproductive system. He has just won one of the most prestigious awards in British urology and his whole career has been built around not just treating men, but understanding them.He has introduced pioneering microsurgical techniques to the North West, and his specialist practice covers everything from erectile dysfunction and testosterone deficiency to complex reconstruction. He founded the Manchester Andrology Research Collaborative, has published over sixty academic papers, and has contributed to international guidelines on men's health across Europe and America. He is also Editor-in-Chief of Trends in Urology and Men's Health.Whether this is relevant to you, or someone you care about, hopefully you will find something useful to take away. Hosted on Acast. See acast.com/privacy for more information.